Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-04-08
2008-04-08
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S069100
Reexamination Certificate
active
07354714
ABSTRACT:
A vaccine against disease caused by papilloma viruses is described in certain embodiments, as well as certain vectors, obtainable by the following methods: (a) one or more expression vectors that contain the DNA code for a structural protein of papilloma viruses or a fragment thereof are injected into mammals, whereby in at least some of the expression vectors randomly generated heterologous sequences are inserted into the DNA code (b) serums are obtained from the mammals and these are tested for the presence of antibodies against particles of various papilloma virus types, and (c) using the serums tested, the structural protein gene clones are identified that code for a polyvalent vaccine, and (d) the vaccine is produced from them. Procedures for producing a vaccine is also described, together with its use for vaccination against diseases caused by papilloma viruses.
REFERENCES:
patent: 4551270 (1985-11-01), Danos et al.
patent: 5045447 (1991-09-01), Minson
patent: 5626877 (1997-05-01), Amsden et al.
patent: 5820870 (1998-10-01), Joyce et al.
patent: 5821087 (1998-10-01), Lowe et al.
patent: 5840306 (1998-11-01), Hofmann et al.
patent: 5866553 (1999-02-01), Donnelly et al.
patent: 5888516 (1999-03-01), Jansen et al.
patent: 5891108 (1999-04-01), Leone et al.
patent: 5972027 (1999-10-01), Johnson
patent: 5981173 (1999-11-01), Orth et al.
patent: 6025163 (2000-02-01), Shamanin et al.
patent: 6041252 (2000-03-01), Walker et al.
patent: 6066324 (2000-05-01), Gissmann et al.
patent: 6071305 (2000-06-01), Brown et al.
patent: 6074673 (2000-06-01), Guillen
patent: 6083996 (2000-07-01), Buyuktimkin et al.
patent: 6086582 (2000-07-01), Altman et al.
patent: 6086912 (2000-07-01), Gilman
patent: 6110498 (2000-08-01), Rudnic et al.
patent: 6126919 (2000-10-01), Stefely et al.
patent: 6132765 (2000-10-01), DiCosmo et al.
patent: 6136295 (2000-10-01), Edwards et al.
patent: 6142939 (2000-11-01), Eppstein et al.
patent: 6183745 (2001-02-01), Tindle et al.
patent: 6221577 (2001-04-01), Muller et al.
patent: 6235312 (2001-05-01), Hobbs et al.
patent: 6235313 (2001-05-01), Mathiowitz et al.
patent: 6245349 (2001-06-01), Yiv et al.
patent: 6245568 (2001-06-01), Volkin et al.
patent: 6251079 (2001-06-01), Gambale et al.
patent: 6251678 (2001-06-01), Volkin et al.
patent: 6283947 (2001-09-01), Mirzaee
patent: 6283949 (2001-09-01), Roorda
patent: 6287792 (2001-09-01), Pardridge et al.
patent: 6296621 (2001-10-01), Masuda et al.
patent: 6296832 (2001-10-01), Ruoslahti et al.
patent: 6309370 (2001-10-01), Haim et al.
patent: 6309375 (2001-10-01), Glines et al.
patent: 6309380 (2001-10-01), Larson et al.
patent: 6309410 (2001-10-01), Kuzma et al.
patent: 6317629 (2001-11-01), Haak et al.
patent: 6346272 (2002-02-01), Viegas et al.
patent: 6350780 (2002-02-01), Garst et al.
patent: 6358744 (2002-03-01), Volkin et al.
patent: 6379382 (2002-04-01), Yang
patent: 6387124 (2002-05-01), Buscemi et al.
patent: 6387397 (2002-05-01), Chen et al.
patent: 6649167 (2003-11-01), Hallek et al.
patent: 199 25 199 (2000-12-01), None
patent: 100 59 631 (2002-07-01), None
patent: WO 93/02184 (1993-02-01), None
patent: WO 95/31532 (1995-11-01), None
patent: WO 98/44944 (1998-10-01), None
patent: WO 00/35479 (2000-06-01), None
patent: WO 00/45841 (2000-08-01), None
patent: WO 01/14416 (2001-03-01), None
patent: WO 01/97840 (2001-12-01), None
patent: WO 03/078455 (2003-09-01), None
Beitburd et al., “Human papillomavirus vaccines,”Cancer Biology, vol. 9, pp. 431-445 (1999).
Chen et al., “Structure of Small virus-like Particles Assembled fromt heL1 Protein of Human Papillomavirus 16”,Mol. Cell5:, 557-567 (2000).
Donnelly et al., “Protection against Papillomavirus with a Polynucleotide Vaccine,”Journal of Infectious Diseases, vol. 713, pp. 314-320 (1996).
Cole et al., “Nucleotide Sequence And Comparative Analysis Of The Human Papillomavirus Type 18 Genome—Phylogeny Of Papillomaviruses and Repeated Structure of the E6 and E7 Gene Products”,J. Mol. Bio., (4); 599-608 (1987).
Giroglou et al., “Immunological analyses of human papillomavirus capsids,”Vaccine, vol. 19, pp. 1783-1793 (2001).
Kennedy et al., “A Negative Regulatory Element in the human Papillomavirus type 16 Genome Acts at the Level of Late mRNA Stability”,J. Virol.65(4), 2093-2097 (1991).
Kotecha et al., “Enhanced tumour growth after DNA Vaccination against Human Papilloma Virus E7 On Coprotein: Evidence for Tumor-Inducted Immune Deviation”Vaccine2003 21 (19-20): 2506-15.
Kowalczyk et al., “Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16,”Vaccine, vol. 19, pp. 3583-3590 (2001).
Leder et al., “Enhancement of Capsid Gene Expression: Preparing the Human Papillomavirus Type 16 Major Structural Gene L1 for DNA Vaccination Purposes,”J. Virol., vol. 75, No. 19, pp. 9201-9209 (Oct. 2001).
Longuet et al., “Two Novel Genital Human Papillomavirus (HPV) Types, HPV68 and HPV70, Related to the Potentially Oncogenic HPV39”,J. Clin. Microbiol. 34 (3), 738-744 (1996).
Pastrana et al., “NHPV16 VLP Vaccine Induces Human Antibodies That Neutralize Divergent Variants of HPV16,”Virology, vol. 279, pp. 361-369 (2001).
Pumpens et al. “Evaluation of HBs, and frCP Virus-Like Particles for Expression of Human Papillomavirus 16 E7 Oncoprotein Epitopes”Intervirology. 2002, 45(1): 24-32.
Roden et al., “Minor Capsid Protein of Human Genital Papillomaviruses Contains Subdominant, Cross-Neutralizing Epitopes,”Virology, vol. 270, pp. 254-257 (2000).
Rudolf et al. “Induction of HPV16 Capsid Protein-Specific Human T Cell Responses by Virus-Like Particles”Biol. Chem. 1999, 380: 335-40.
Schreckenberger et al., “Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization,”Vaccine, vol. 19, pp. 227-233 (2001).
Sundaram et al., “Intracutaneous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) L1 gene protects against virus challenge,”Vaccine, vol. 15, No. 6/7, pp. 664-671 (1997).
Touze et al., “The L1 Major Capsid Protein of Human Papillomavirus Type 16 Variants Affects Yield of Virus-Like Particles Produced in an Insect Cell Expression System,”J. Clin. Microbiol., vol. 36, No. 7, pp. 2046-2051 (Jul. 1998).
Xu et al., “Identification of a Novel Mechanism for endotoxin-mediated Down-Modulation of CC Chemokine Receptor Expression”Eur. J. Immunol. 2000, 30: 228-9.
Chen et al., “Structure of Small Virus-like Particles Assembled from the L1 Protein of Human Papillomavirus 16”,Molecular Cell, vol. 5, pp. 557-567, Mar. 2000.
Gissmann Lutz
Möller Martin
Pohlmeyer Kai
Deutsches Krebsforschungszentrum Stiftung des öffentlichen
Patterson Thuente Skaar & Christensen P.A.
Salimi Ali R.
LandOfFree
Production and applications for polyvalent vaccines against... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Production and applications for polyvalent vaccines against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production and applications for polyvalent vaccines against... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2786723